Laura Müller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Laura Müller has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Ali Ebrahimifard
Department of Nuclear Medicine, University Hospital Marburg, Philipps University Marburg, 35043 Marburg, Germany
3 shared publications - Behrooz Hooshyar Yousefi
Department of Nuclear Medicine, University Hospital Marburg, Philipps University Marburg, 35043 Marburg, Germany
3 shared publications - Friederike Eilsberger
Department of Nuclear Medicine, University Hospital Marburg, Philipps University Marburg, 35043 Marburg, Germany
3 shared publications - Markus Luster
Department of Nuclear Medicine, University Hospital Marburg, Philipps University Marburg, 35043 Marburg, Germany
3 shared publications - Pietro Di Fazio
Department of Nuclear Medicine, University Hospital Marburg, Philipps University Marburg, 35043 Marburg, Germany
3 shared publications - Qi Wang
Department of Nuclear Medicine, School of Medicine, Philipps-University Marburg, 35043 Marburg, Germany
3 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (20) , 9330
Multimodal Evaluation of [225Ac]Ac-PSMA-617 Therapy in mCRPC: PET Based Total Tumor Volume, PSA Kinetics, and Blood Biomarkers
This retrospective analysis interrogates the value of a multimodal biomarker paradigm to characterize molecular and clinical responses to [225Ac]Ac-PSMA-617-targeted α-therapy (TAT) in cohorts of heavily pretreated metastatic castration-resistant prostate cancer patients who had shown limited benefit from prior [177Lu]Lu-PSMA-617. By integrating quantitative PSMA-PET/CT metrics—notably total tumor volume (TTV) and lesion SUV indices—with longitudinal PSA kinetics, routine hematologic and biochemical markers, and semiquantitative assessment of salivary gland uptake, we sought to delineate treatment effect, organ-specific off-target impact, and prognostic biomarker signatures. In twelve patients receiving 2–6 cycles of therapy (median activity 8 MBq), biochemical responses were frequent: 8/12 experienced PSA declines and 5/12 achieved ≥50% reduction. Concordant molecular responses were observed on PSMA-PET, with SUVpeak-based partial response in 7/12, stable disease in 3/12, and progressive disease in 2/12 of the target lesions. Qualitative concordance between TTV and PSA response was observed in four illustrative patients; no formal cohort-level concordance analysis was performed. Notably, salivary gland tracer uptake on [68Ga]Ga-PSMA-11 PET/CT decreased after two cycles of [225Ac]Ac-PSMA-617 compared with baseline (SUVmax −63.7%; SUVmean −45.5%). In this exploratory cohort, elevations in PSA, alkaline phosphatase, and LDH measured after two cycles of therapy, along with low hemoglobin, platelet count, and creatinine, were associated with shorter overall survival. Median progression-free survival and overall survival were 27 and 53 weeks, respectively. Collectively, these findings suggest that a combined PSMA-PET TTV–PSA–blood biomarker framework may offer complementary insight alongside PSA alone for characterizing therapeutic response, although its incremental value over PSA was not formally tested in this exploratory cohort; blood-based biomarkers (PSA, ALP) showed the most consistent prognostic association with survival, providing objective measures of both tumor response and collateral tissue impact. Prospective validation in larger, controlled cohorts is warranted to refine biomarker thresholds and guide personalized TAT strategies.
- 20 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (20) , 9330
Open AccessMultimodal Evaluation of [225Ac]Ac-PSMA-617 Therapy in mCRPC: PET Based Total Tumor Volume, PSA Kinetics, and Blood Biomarkers
This retrospective analysis interrogates the value of a multimodal biomarker paradigm to characterize molecular and clinical responses to [225Ac]Ac-PSMA-617-targeted α-therapy (TAT) in cohorts of heavily pretreated metastatic castration-resistant prostate cancer patients who had shown limited benefit from prior [177Lu]Lu-PSMA-617. By integrating quantitative PSMA-PET/CT metrics—notably total tumor volume (TTV) and lesion SUV indices—with longitudinal PSA kinetics, routine hematologic and biochemical markers, and semiquantitative assessment of salivary gland uptake, we sought to delineate treatment effect, organ-specific off-target impact, and prognostic biomarker signatures. In twelve patients receiving 2–6 cycles of therapy (median activity 8 MBq), biochemical responses were frequent: 8/12 experienced PSA declines and 5/12 achieved ≥50% reduction. Concordant molecular responses were observed on PSMA-PET, with SUVpeak-based partial response in 7/12, stable disease in 3/12, and progressive disease in 2/12 of the target lesions. Qualitative concordance between TTV and PSA response was observed in four illustrative patients; no formal cohort-level concordance analysis was performed. Notably, salivary gland tracer uptake on [68Ga]Ga-PSMA-11 PET/CT decreased after two cycles of [225Ac]Ac-PSMA-617 compared with baseline (SUVmax −63.7%; SUVmean −45.5%). In this exploratory cohort, elevations in PSA, alkaline phosphatase, and LDH measured after two cycles of therapy, along with low hemoglobin, platelet count, and creatinine, were associated with shorter overall survival. Median progression-free survival and overall survival were 27 and 53 weeks, respectively. Collectively, these findings suggest that a combined PSMA-PET TTV–PSA–blood biomarker framework may offer complementary insight alongside PSA alone for characterizing therapeutic response, although its incremental value over PSA was not formally tested in this exploratory cohort; blood-based biomarkers (PSA, ALP) showed the most consistent prognostic association with survival, providing objective measures of both tumor response and collateral tissue impact. Prospective validation in larger, controlled cohorts is warranted to refine biomarker thresholds and guide personalized TAT strategies.
- Open Access
- 26 February 2026
- Published by MDPI AG in Preprints.org
[225Ac]Ac-PSMA Therapy in mCRPC: Early Efficacy and Biomarker Trends in a Selected Patient Population
This study evaluates the efficacy and safety of [²²⁵Ac]Ac-PSMA-617 targeted alpha therapy (TAT) in patients with metastatic castration-resistant prostate cancer (mCRPC) who demonstrated Prostate-Specific Antigen (PSA) based non-responsiveness to prior [¹⁷⁷Lu]Lu-PSMA-617 therapy. Moving beyond traditional PSA-level assessments, we integrate blood biomarkers, PSMA-PET based total tumor volume (TTV) and salivary glands uptake. This retrospective analysis provides a comprehensive framework for evaluating treatment efficacy. Twelve patients underwent 2–6 cycles of [²²⁵Ac]Ac-PSMA-617, with a median activity of 8 MBq. PSA decline was observed in 8/12 patients, with 5/12 achieving a > 50% reduction. TTV results showed partial response in 7/12, stable disease in 3/12, and progression in 2/12, correlating strongly with PSA trends. Salivary glands showed significantly lower post-TAT PSMA-PET SUVmax and SUVmean (-63.7% and -45.5%, respectively). Moreover, elevated PSA, ALP, and LDH, along with low hemoglobin, platelet count, and creatinine, were associated with reduced overall survival (OS). Median progression-free survival (PFS) and OS were 27 and 53 weeks, respectively. The Barthel Index remained stable indicating preserved functional independence. These findings suggest that combining PSA, TTV, and blood biomarkers enhances the predictive accuracy and supports a more holistic evaluation of treatment efficacy. Validation in larger cohorts is warranted.
- 26 February 2026
- Published by MDPI AG in Preprints.org
Open Access[225Ac]Ac-PSMA Therapy in mCRPC: Early Efficacy and Biomarker Trends in a Selected Patient Population
This study evaluates the efficacy and safety of [²²⁵Ac]Ac-PSMA-617 targeted alpha therapy (TAT) in patients with metastatic castration-resistant prostate cancer (mCRPC) who demonstrated Prostate-Specific Antigen (PSA) based non-responsiveness to prior [¹⁷⁷Lu]Lu-PSMA-617 therapy. Moving beyond traditional PSA-level assessments, we integrate blood biomarkers, PSMA-PET based total tumor volume (TTV) and salivary glands uptake. This retrospective analysis provides a comprehensive framework for evaluating treatment efficacy. Twelve patients underwent 2–6 cycles of [²²⁵Ac]Ac-PSMA-617, with a median activity of 8 MBq. PSA decline was observed in 8/12 patients, with 5/12 achieving a > 50% reduction. TTV results showed partial response in 7/12, stable disease in 3/12, and progression in 2/12, correlating strongly with PSA trends. Salivary glands showed significantly lower post-TAT PSMA-PET SUVmax and SUVmean (-63.7% and -45.5%, respectively). Moreover, elevated PSA, ALP, and LDH, along with low hemoglobin, platelet count, and creatinine, were associated with reduced overall survival (OS). Median progression-free survival (PFS) and OS were 27 and 53 weeks, respectively. The Barthel Index remained stable indicating preserved functional independence. These findings suggest that combining PSA, TTV, and blood biomarkers enhances the predictive accuracy and supports a more holistic evaluation of treatment efficacy. Validation in larger cohorts is warranted.
- Open Access
- 20 November 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 710
Current clinical standards for renal transplantation: a survey among urological and surgical transplantation centers in Germany
Purpose: Kidney transplants in Germany are either performed by surgical, urological or interdisciplinary teams. Hence, perioperative details might differ in relevant ways. The aim of our survey was to record and compare the respective perioperative standards. Methods: A structured 50-item questionnaire was sent via email to all certified German kidney transplant centers ( n = 38). Anonymized data collection was performed with www.surveymonkey.com from November 2023 – May 2024. Results: Complete responses were obtained from 34/38 centers (response rate 89.5%); 13 were urological-led and 21 surgical-led programs. In most cases (76% urological vs. 90% surgical, n = 10 and 19), transplantation is performed extraperitoneally via hockey-stick incision. A peritoneal fenestration for lymphocele prophylaxis is not performed routinely (69% vs. 86%, n = 9 and 18). Vascular anastomoses are primarily frequently sutured with 5 − 0 or 6 − 0 prolene, and the ureteral anastomosis with 4 − 0, 5 − 0 or 6 − 0 PDS suture. The Lich-Gregoir technique is most commonly used for ureteral implantation (84% in urology vs. 76% in surgery, p = 0,55). There are only small differences in postoperative management between urological and surgical programs, e.g. regarding the duration of catheterization (7–10 days vs. < 7 days; p = 0.008) or the time of discharge (10–14 days vs. 6–8 days; p = 0,05). Conclusion: The majority of kidney transplants in Germany is performed according to similar standards. There are minor differences in the specialists approach, e.g. in the choice of suture material. Certain practices, such as peritoneal fenestration for lymphocele prophylaxis, warrant further scientific evaluation.
- 20 November 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 710
Open AccessCurrent clinical standards for renal transplantation: a survey among urological and surgical transplantation centers in Germany
Purpose: Kidney transplants in Germany are either performed by surgical, urological or interdisciplinary teams. Hence, perioperative details might differ in relevant ways. The aim of our survey was to record and compare the respective perioperative standards. Methods: A structured 50-item questionnaire was sent via email to all certified German kidney transplant centers ( n = 38). Anonymized data collection was performed with www.surveymonkey.com from November 2023 – May 2024. Results: Complete responses were obtained from 34/38 centers (response rate 89.5%); 13 were urological-led and 21 surgical-led programs. In most cases (76% urological vs. 90% surgical, n = 10 and 19), transplantation is performed extraperitoneally via hockey-stick incision. A peritoneal fenestration for lymphocele prophylaxis is not performed routinely (69% vs. 86%, n = 9 and 18). Vascular anastomoses are primarily frequently sutured with 5 − 0 or 6 − 0 prolene, and the ureteral anastomosis with 4 − 0, 5 − 0 or 6 − 0 PDS suture. The Lich-Gregoir technique is most commonly used for ureteral implantation (84% in urology vs. 76% in surgery, p = 0,55). There are only small differences in postoperative management between urological and surgical programs, e.g. regarding the duration of catheterization (7–10 days vs. < 7 days; p = 0.008) or the time of discharge (10–14 days vs. 6–8 days; p = 0,05). Conclusion: The majority of kidney transplants in Germany is performed according to similar standards. There are minor differences in the specialists approach, e.g. in the choice of suture material. Certain practices, such as peritoneal fenestration for lymphocele prophylaxis, warrant further scientific evaluation.
- Open Access
Therapeutic Consequences of 68Ga-PSMA-11-PET/CT in Prostate Cancer in Correlation to the Gleason Score, PSA Value, and D’Amico-Defined Risk Groups
Background/Objectives: The aim of this study was to demonstrate the importance of 68Gallium (68Ga)–prostate specific membrane antigen (PSMA)–positron emissions tomography (PET)/computed tomography (CT)(PET/CT) in prostate cancer patients for therapy management with individual analyses regarding the Gleason score, prostate specific antigen (PSA) value, and the risk groups defined by D’Amico. Methods: We retrospectively analyzed 562 68Ga-PSMA-11-PET/CT examinations performed from January 2015 to March 2023 at University Hospital Marburg. We assessed treatment changes post 68Ga-PSMA-11-PET/CT and categorized the cases based on PSA values, Gleason scores, and D’Amico risk groups. Results: In 415/562 (73.8%) of 68Ga-PSMA-11-PET/CT examinations, a modification in the therapy concept was recorded. Patients categorized as high risk or patients with Gleason scores of 7 through 10 or with PSA levels above 0.5 ng/mL (particularly within the ranges of 1.01–2 ng/mL, 3.01–5 ng/mL, and values exceeding 10 ng/mL) demonstrated a statistically significant association with treatment change. While no evidence of the disease was found most frequently in 38% of cases in the “Therapy continued without explicit reference” group, in the group with the adapted therapy, there was a considerable higher proportion of local tumors (19.2%) compared to the other groups (4.4% and 1.4%). Conclusions: Our results show the high impact of 68Ga-PSMA-PET/CT for patients with prostate cancer regarding therapy management planning, which is even more important for some patient groups.
Open AccessTherapeutic Consequences of 68Ga-PSMA-11-PET/CT in Prostate Cancer in Correlation to the Gleason Score, PSA Value, and D’Amico-Defined Risk Groups
Background/Objectives: The aim of this study was to demonstrate the importance of 68Gallium (68Ga)–prostate specific membrane antigen (PSMA)–positron emissions tomography (PET)/computed tomography (CT)(PET/CT) in prostate cancer patients for therapy management with individual analyses regarding the Gleason score, prostate specific antigen (PSA) value, and the risk groups defined by D’Amico. Methods: We retrospectively analyzed 562 68Ga-PSMA-11-PET/CT examinations performed from January 2015 to March 2023 at University Hospital Marburg. We assessed treatment changes post 68Ga-PSMA-11-PET/CT and categorized the cases based on PSA values, Gleason scores, and D’Amico risk groups. Results: In 415/562 (73.8%) of 68Ga-PSMA-11-PET/CT examinations, a modification in the therapy concept was recorded. Patients categorized as high risk or patients with Gleason scores of 7 through 10 or with PSA levels above 0.5 ng/mL (particularly within the ranges of 1.01–2 ng/mL, 3.01–5 ng/mL, and values exceeding 10 ng/mL) demonstrated a statistically significant association with treatment change. While no evidence of the disease was found most frequently in 38% of cases in the “Therapy continued without explicit reference” group, in the group with the adapted therapy, there was a considerable higher proportion of local tumors (19.2%) compared to the other groups (4.4% and 1.4%). Conclusions: Our results show the high impact of 68Ga-PSMA-PET/CT for patients with prostate cancer regarding therapy management planning, which is even more important for some patient groups.
- Open Access
- 9 March 2023
- Published by Springer Nature in Die Urologie
- Vol. 62 (5) , 503-509
Versorgungsstruktur der ambulanten Urologie in Deutschland
Zusammenfassung: Hintergrund: Obwohl urologische Facharztpraxen zentraler Pfeiler der ambulanten Patientenversorgung in Deutschland sind, fehlen hierzu aktuelle Daten. Eine Beschreibung der Strukturen in Großstädten gegenüber dem ländlichen Raum sowie von Gendereffekten und Generationsunterschieden ist auch als Ausgangsbasis für weitere Untersuchungen erforderlich. Material und Methoden: Die Erhebung umfasst Daten des Arztverzeichnisses der Stiftung Gesundheit sowie der Bundesärztekammer und des Statistischen Bundesamtes. Die erfassten Praxen bzw. Kolleg*innen wurden in Subgruppen eingeteilt. Anhand der unterschiedlichen Subgruppengröße lassen sich Aussagen über die Versorgungsstruktur der ambulanten Urologie in Deutschland treffen. Ergebnisse: Während in größeren Städten die Mehrheit der niedergelassenen Urolog*innen in Berufsausübungsgemeinschaften (BAG) arbeitet und durchschnittlich weniger Patient*innen betreut, zeigt sich im ländlichen Raum ein besonders hoher Anteil an Einzelpraxen mit mehr zu versorgenden Einwohnern pro Urolog*in. Urologinnen arbeiten häufiger in der stationären Versorgung. Wenn sich Fachärztinnen für Urologie für die Niederlassung entscheiden, dann eher in BAG und eher in städtischen Gebieten. Außerdem zeigt sich eine Verschiebung der Geschlechterverteilung: Je jünger die betrachtete Alterssubgruppe, desto höher liegt der Anteil an Urologinnen unter allen Kolleg*innen. Schlussfolgerung: Wir beschreiben erstmalig die tatsächliche Versorgungsstruktur der ambulanten Urologie in Deutschland. Hierbei deuten sich Trends an, die die Art zu arbeiten und die Patientenversorgung in einigen Jahren maßgeblich beeinflussen werden.
- 9 March 2023
- Published by Springer Nature in Die Urologie
- Vol. 62 (5) , 503-509
Open AccessVersorgungsstruktur der ambulanten Urologie in Deutschland
Zusammenfassung: Hintergrund: Obwohl urologische Facharztpraxen zentraler Pfeiler der ambulanten Patientenversorgung in Deutschland sind, fehlen hierzu aktuelle Daten. Eine Beschreibung der Strukturen in Großstädten gegenüber dem ländlichen Raum sowie von Gendereffekten und Generationsunterschieden ist auch als Ausgangsbasis für weitere Untersuchungen erforderlich. Material und Methoden: Die Erhebung umfasst Daten des Arztverzeichnisses der Stiftung Gesundheit sowie der Bundesärztekammer und des Statistischen Bundesamtes. Die erfassten Praxen bzw. Kolleg*innen wurden in Subgruppen eingeteilt. Anhand der unterschiedlichen Subgruppengröße lassen sich Aussagen über die Versorgungsstruktur der ambulanten Urologie in Deutschland treffen. Ergebnisse: Während in größeren Städten die Mehrheit der niedergelassenen Urolog*innen in Berufsausübungsgemeinschaften (BAG) arbeitet und durchschnittlich weniger Patient*innen betreut, zeigt sich im ländlichen Raum ein besonders hoher Anteil an Einzelpraxen mit mehr zu versorgenden Einwohnern pro Urolog*in. Urologinnen arbeiten häufiger in der stationären Versorgung. Wenn sich Fachärztinnen für Urologie für die Niederlassung entscheiden, dann eher in BAG und eher in städtischen Gebieten. Außerdem zeigt sich eine Verschiebung der Geschlechterverteilung: Je jünger die betrachtete Alterssubgruppe, desto höher liegt der Anteil an Urologinnen unter allen Kolleg*innen. Schlussfolgerung: Wir beschreiben erstmalig die tatsächliche Versorgungsstruktur der ambulanten Urologie in Deutschland. Hierbei deuten sich Trends an, die die Art zu arbeiten und die Patientenversorgung in einigen Jahren maßgeblich beeinflussen werden.